 7. Clinically significant cardiovascular disease including: a Myocardial infarction within 6 months of Screening visit; b Uncontrolled angina within 3 months of Screening visit; c Congestive heart failure New York Heart Association NYHA class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione mitoxantrone treatment, unless a screening echocardiogram or multi-gated acquisition scan MUGA performed within three months of the Screening visit results in a left ventricular ejection fraction that is 50; d History of clinically significant ventricular arrhythmias e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes; e Prolonged corrected QT interval by the Fridericia correction formula QTcF on the screening Electrocardiogram ECG 470 msec; f History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place; 